Umlaut Bio raises €10.0M Seed round
8 July 2024· Heidelberg, Germany· health, oncology, biotech, b2b, software_hardware
The funding is used to advance R&D efforts and leverage a proprietary platform for developing small molecule therapies targeting tRNA modifications in cancer and autoimmune diseases.
Investors
LeadHigh-Tech Gründerfonds
Also participating
L-BankLBBW Venture CapitalMission BioCapitalOno PharmaceuticalEli LillyAbbVie
About Umlaut Bio
Stage
Seed
Headquarters
Heidelberg, Germany
Founded
2022
Team Size
6–20
Sectors
healthoncologybiotechb2bsoftware_hardware